B-intervention	0	11	Neoadjuvant
I-intervention	12	24	chemotherapy
I-intervention	25	29	with
I-intervention	30	41	trastuzumab
O	42	50	followed
O	51	53	by
O	54	62	adjuvant
O	63	74	trastuzumab
O	75	81	versus
B-control	82	93	neoadjuvant
I-control	94	106	chemotherapy
I-control	107	112	alone
O	112	113	,
O	114	116	in
O	117	125	patients
O	126	130	with
O	131	135	HER2
O	135	136	-
O	136	144	positive
O	145	152	locally
O	153	161	advanced
O	162	168	breast
O	169	175	cancer
O	176	177	(
O	177	180	the
O	181	185	NOAH
O	186	191	trial
O	191	192	)
O	192	193	:
O	194	195	a
O	196	206	randomised
O	207	217	controlled
O	218	229	superiority
O	230	235	trial
O	236	240	with
O	241	242	a
O	243	251	parallel
O	252	256	HER2
O	256	257	-
O	257	265	negative
O	266	272	cohort
O	272	273	.

O	274	277	The
O	278	288	monoclonal
O	289	297	antibody
O	298	309	trastuzumab
O	310	313	has
O	314	322	survival
O	323	330	benefit
O	331	335	when
O	336	341	given
O	342	346	with
O	347	359	chemotherapy
O	360	362	to
O	363	371	patients
O	372	376	with
O	377	382	early
O	382	383	,
O	384	392	operable
O	392	393	,
O	394	397	and
O	398	408	metastatic
O	409	415	breast
O	416	422	cancer
O	423	427	that
O	428	431	has
O	432	436	HER2
O	437	438	(
O	438	442	also
O	443	448	known
O	449	451	as
O	452	457	ERBB2
O	457	458	)
O	459	473	overexpression
O	474	476	or
O	477	490	amplification
O	490	491	.

O	492	494	We
O	495	500	aimed
O	501	503	to
O	504	510	assess
O	511	516	event
O	516	517	-
O	517	521	free
O	522	530	survival
O	531	533	in
B-eligibility	534	542	patients
I-eligibility	543	547	with
I-eligibility	548	552	HER2
I-eligibility	552	553	-
I-eligibility	553	561	positive
I-eligibility	562	569	locally
I-eligibility	570	578	advanced
I-eligibility	579	581	or
I-eligibility	582	594	inflammatory
I-eligibility	595	601	breast
I-eligibility	602	608	cancer
I-eligibility	609	618	receiving
I-eligibility	619	630	neoadjuvant
I-eligibility	631	643	chemotherapy
O	644	648	with
O	649	651	or
O	652	659	without
O	660	661	1
O	662	666	year
O	667	669	of
O	670	681	trastuzumab
O	681	682	.

O	683	685	We
O	686	694	compared
O	695	696	1
O	697	701	year
O	702	704	of
O	705	714	treatment
O	715	719	with
O	720	731	trastuzumab
O	732	733	(
O	733	738	given
O	739	741	as
O	742	753	neoadjuvant
O	754	757	and
O	758	766	adjuvant
O	767	776	treatment
O	776	777	;
O	778	779	n
O	779	780	=
B-intervention-participants	780	783	117
O	783	784	)
O	785	789	with
O	790	792	no
O	793	804	trastuzumab
O	805	806	(
B-control-participants	806	809	118
O	809	810	)
O	810	811	,
O	812	814	in
O	815	820	women
O	821	825	with
O	826	830	HER2
O	830	831	-
O	831	839	positive
O	840	847	locally
O	848	856	advanced
O	857	859	or
O	860	872	inflammatory
O	873	879	breast
O	880	886	cancer
O	887	894	treated
O	895	899	with
O	900	901	a
O	902	913	neoadjuvant
O	914	926	chemotherapy
O	927	934	regimen
O	935	945	consisting
O	946	948	of
O	949	960	doxorubicin
O	960	961	,
O	962	972	paclitaxel
O	972	973	,
O	974	990	cyclophosphamide
O	990	991	,
O	992	1004	methotrexate
O	1004	1005	,
O	1006	1009	and
O	1010	1022	fluorouracil
O	1022	1023	.

O	1024	1037	Randomisation
O	1038	1041	was
O	1042	1046	done
O	1047	1051	with
O	1052	1053	a
O	1054	1062	computer
O	1063	1070	program
O	1071	1074	and
O	1075	1087	minimisation
O	1088	1097	technique
O	1097	1098	,
O	1099	1105	taking
O	1106	1113	account
O	1114	1116	of
O	1117	1129	geographical
O	1130	1134	area
O	1134	1135	,
O	1136	1143	disease
O	1144	1149	stage
O	1149	1150	,
O	1151	1154	and
O	1155	1162	hormone
O	1163	1171	receptor
O	1172	1178	status
O	1178	1179	.

O	1180	1193	Investigators
O	1194	1198	were
O	1199	1207	informed
O	1208	1210	of
O	1211	1220	treatment
O	1221	1231	allocation
O	1231	1232	.

O	1233	1234	A
O	1235	1243	parallel
O	1244	1250	cohort
O	1251	1253	of
O	1254	1256	99
O	1257	1265	patients
O	1266	1270	with
O	1271	1275	HER2
O	1275	1276	-
O	1276	1284	negative
O	1285	1292	disease
O	1293	1296	was
O	1297	1305	included
O	1306	1309	and
O	1310	1317	treated
O	1318	1322	with
O	1323	1326	the
O	1327	1331	same
O	1332	1344	chemotherapy
O	1345	1352	regimen
O	1352	1353	.

O	1354	1361	Primary
O	1362	1370	endpoint
O	1371	1374	was
B-outcome-Measure	1375	1380	event
I-outcome-Measure	1380	1381	-
I-outcome-Measure	1381	1385	free
I-outcome-Measure	1386	1394	survival
O	1394	1395	.

O	1396	1404	Analysis
O	1405	1408	was
O	1409	1411	by
O	1412	1421	intention
O	1422	1424	to
O	1425	1430	treat
O	1430	1431	.

O	1432	1436	This
O	1437	1442	study
O	1443	1445	is
O	1446	1456	registered
O	1456	1457	,
O	1458	1464	number
O	1465	1479	ISRCTN86043495
O	1479	1480	.

O	1481	1492	Trastuzumab
O	1493	1506	significantly
O	1507	1515	improved
B-outcome	1516	1521	event
I-outcome	1521	1522	-
I-outcome	1522	1526	free
I-outcome	1527	1535	survival
O	1536	1538	in
O	1539	1547	patients
O	1548	1552	with
O	1553	1557	HER2
O	1557	1558	-
O	1558	1566	positive
O	1567	1573	breast
O	1574	1580	cancer
O	1581	1582	(
B-outcome	1582	1583	3
I-outcome	1583	1584	-
I-outcome	1584	1588	year
I-outcome	1589	1594	event
I-outcome	1594	1595	-
I-outcome	1595	1599	free
I-outcome	1600	1608	survival
O	1608	1609	,
B-iv-bin-percent	1610	1612	71
I-iv-bin-percent	1612	1613	%
O	1614	1615	[
O	1615	1617	95
O	1617	1618	%
O	1619	1621	CI
O	1622	1624	61
O	1624	1625	-
O	1625	1627	78
O	1627	1628	;
O	1629	1630	n
O	1630	1631	=
O	1631	1633	36
O	1634	1640	events
O	1640	1641	]
O	1642	1646	with
O	1647	1658	trastuzumab
O	1658	1659	,
O	1660	1662	vs
B-cv-bin-percent	1663	1665	56
I-cv-bin-percent	1665	1666	%
O	1667	1668	[
O	1668	1670	46
O	1670	1671	-
O	1671	1673	65
O	1673	1674	;
O	1675	1676	n
O	1676	1677	=
O	1677	1679	51
O	1680	1686	events
O	1686	1687	]
O	1688	1695	without
O	1695	1696	;
O	1697	1703	hazard
O	1704	1709	ratio
O	1710	1711	0
O	1711	1712	.
O	1712	1714	59
O	1715	1716	[
O	1716	1718	95
O	1718	1719	%
O	1720	1722	CI
O	1723	1724	0
O	1724	1725	.
O	1725	1727	38
O	1727	1728	-
O	1728	1729	0
O	1729	1730	.
O	1730	1732	90
O	1732	1733	]
O	1733	1734	;
O	1735	1736	p
O	1736	1737	=
O	1737	1738	0
O	1738	1739	.
O	1739	1742	013
O	1742	1743	)
O	1743	1744	.

O	1745	1756	Trastuzumab
O	1757	1760	was
O	1761	1765	well
O	1766	1775	tolerated
O	1776	1779	and
O	1779	1780	,
O	1781	1788	despite
O	1789	1799	concurrent
O	1800	1814	administration
O	1815	1819	with
O	1820	1831	doxorubicin
O	1831	1832	,
O	1833	1837	only
B-iv-bin-abs	1838	1841	two
O	1842	1850	patients
O	1851	1852	(
B-iv-bin-percent	1852	1853	2
I-iv-bin-percent	1853	1854	%
O	1854	1855	)
O	1856	1865	developed
B-outcome	1866	1877	symptomatic
I-outcome	1878	1885	cardiac
I-outcome	1886	1893	failure
O	1893	1894	.

O	1895	1899	Both
O	1900	1909	responded
O	1910	1912	to
O	1913	1920	cardiac
O	1921	1926	drugs
O	1926	1927	.

O	1928	1931	The
O	1932	1940	addition
O	1941	1943	of
O	1944	1955	neoadjuvant
O	1956	1959	and
O	1960	1968	adjuvant
O	1969	1980	trastuzumab
O	1981	1983	to
O	1984	1995	neoadjuvant
O	1996	2008	chemotherapy
O	2009	2015	should
O	2016	2018	be
O	2019	2029	considered
O	2030	2033	for
O	2034	2039	women
O	2040	2044	with
O	2045	2049	HER2
O	2049	2050	-
O	2050	2058	positive
O	2059	2066	locally
O	2067	2075	advanced
O	2076	2078	or
O	2079	2091	inflammatory
O	2092	2098	breast
O	2099	2105	cancer
O	2106	2108	to
O	2109	2116	improve
O	2117	2122	event
O	2122	2123	-
O	2123	2127	free
O	2128	2136	survival
O	2136	2137	,
O	2138	2146	survival
O	2146	2147	,
O	2148	2151	and
O	2152	2160	clinical
O	2161	2164	and
O	2165	2177	pathological
O	2178	2184	tumour
O	2185	2194	responses
O	2194	2195	.

O	2196	2197	F
O	2198	2206	Hoffmann
O	2206	2207	-
O	2207	2209	La
O	2210	2215	Roche
O	2215	2216	.
